Organisation paid for research Program year 2025 Source: CMS Open Payments

Weitzner, Yonker, Kaine MD.

Neither a doctor nor a teaching hospital

Research payments

$242,352

10 payments

Through program year 2025, Weitzner, Yonker, Kaine MD. is reported as receiving $242,352 in research payments, across 10 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$106,499	6
2023	Research	$6,061	1
2022	Research	$124,645	2
2019	Research	$5,147	1

Breakdown

Who paid Research payments · program years 2019–2025

Ucb SA $237,205 9 payments
Amgen Inc. $5,147 1 payment

Studies the money was for Research payments · program years 2019–2025

A Multi-Center, Open-Label Study to Evaluate the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis Using An Electrochemiluminescent Immuno-Assay $116,465 2 payments
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. $72,121 1 payment
A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis $14,241 1 payment
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $14,097 2 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $13,000 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $6,382 1 payment
ABP 710 Ph3 RA Multi-Dose Global $5,147 1 payment
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis $900 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.